The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...
Read MoreKancera AB (Kancera) has previously reported the initial top line results from the FRACTAL study and today Kancera presents the statistical analyses that confirm that: the primary objective was met, by showing that KAND567 was safe and well tolerated...
Read MoreKancera AB (publ) today reports the top line results from the FRACTAL study, a double-blinded placebo-controlled, explorative phase IIa study of Kancera’s fractalkine blocker KAND567 in high-risk ST-elevation myocardial infarction (STEMI) patients undergoing acute percutaneous coronary intervention (PCI). The...
Read MoreIn connection with the release of the financial interim report for the third quarter of 2023, Kancera AB (publ) provides an operational update regarding its fractalkine blockers KAN567 and KAND145, both in clinical stage. Further, the company reports that...
Read MoreThe period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...
Read MoreKancera AB (publ) today reports that the Finnish regulatory agency (FIMEA) has approved Kancera’s application to conduct a phase I study of KAND145, the company’s second generation fractalkine blocking candidate drug.
Read MoreKancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.
Read MoreKancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Read MoreIn connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from the ongoing FRACTAL study are expected to be presented...
Read MoreThe period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 16.5 million (SEK 14.7 million). Operating income for the second quarter amounted to SEK...
Read More